299 related articles for article (PubMed ID: 31995639)
21. Highlights into the pharmacology of nutraceuticals.
Andrew R; Izzo AA
Br J Pharmacol; 2020 Mar; 177(6):1209-1211. PubMed ID: 32133625
[TBL] [Abstract][Full Text] [Related]
22. Mitochondrial pharmacology: featured mechanisms and approaches for therapy translation.
Wang X; Galli G; Campanella M
Br J Pharmacol; 2019 Nov; 176(22):4245-4246. PubMed ID: 31793696
[TBL] [Abstract][Full Text] [Related]
23. Heart failure is associated with exaggerated endothelial ischaemia-reperfusion injury and attenuated effect of ischaemic preconditioning.
Seeger JP; Benda NM; Riksen NP; van Dijk AP; Bellersen L; Hopman MT; Cable NT; Thijssen DH
Eur J Prev Cardiol; 2016 Jan; 23(1):33-40. PubMed ID: 25389072
[TBL] [Abstract][Full Text] [Related]
24. Current and future treatments of pulmonary arterial hypertension.
Sommer N; Ghofrani HA; Pak O; Bonnet S; Provencher S; Sitbon O; Rosenkranz S; Hoeper MM; Kiely DG
Br J Pharmacol; 2021 Jan; 178(1):6-30. PubMed ID: 32034759
[TBL] [Abstract][Full Text] [Related]
25. Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy.
Chelladurai P; Boucherat O; Stenmark K; Kracht M; Seeger W; Bauer UM; Bonnet S; Pullamsetti SS
Br J Pharmacol; 2021 Jan; 178(1):54-71. PubMed ID: 31749139
[TBL] [Abstract][Full Text] [Related]
26. Dysregulation of BMP9/BMPR2/SMAD signalling pathway contributes to pulmonary fibrosis and pulmonary hypertension induced by bleomycin in rats.
Jiang Q; Liu C; Liu S; Lu W; Li Y; Luo X; Ma R; Zhang C; Chen H; Chen Y; Zhang Z; Hong C; Guo W; Wang T; Yang K; Wang J
Br J Pharmacol; 2021 Jan; 178(1):203-216. PubMed ID: 33080042
[TBL] [Abstract][Full Text] [Related]
27. Sarcolemmal dependence of cardiac protection and stress-resistance: roles in aged or diseased hearts.
See Hoe LE; May LT; Headrick JP; Peart JN
Br J Pharmacol; 2016 Oct; 173(20):2966-91. PubMed ID: 27439627
[TBL] [Abstract][Full Text] [Related]
28. Rapid ventricular pacing-induced postconditioning attenuates reperfusion injury: effects on peroxynitrite, RISK and SAFE pathways.
Pipicz M; Varga ZV; Kupai K; Gáspár R; Kocsis GF; Csonka C; Csont T
Br J Pharmacol; 2015 Jul; 172(14):3472-83. PubMed ID: 25827015
[TBL] [Abstract][Full Text] [Related]
29. A recent history of nitroxyl chemistry, pharmacology and therapeutic potential.
Fukuto JM
Br J Pharmacol; 2019 Jan; 176(2):135-146. PubMed ID: 29859009
[TBL] [Abstract][Full Text] [Related]
30. The mitochondrion as a key regulator of ischaemic tolerance and injury.
Silachev DN; Plotnikov EY; Pevzner IB; Zorova LD; Babenko VA; Zorov SD; Popkov VA; Jankauskas SS; Zinchenko VP; Sukhikh GT; Zorov DB
Heart Lung Circ; 2014 Oct; 23(10):897-904. PubMed ID: 25043581
[TBL] [Abstract][Full Text] [Related]
31. From primordial gas to the medicine cabinet.
Papapetropoulos A; Wallace JL; Wang R
Br J Pharmacol; 2020 Feb; 177(4):715-719. PubMed ID: 31726475
[TBL] [Abstract][Full Text] [Related]
32. Challenges in the development and exploitation of new therapeutic options targeting the histaminergic system.
Chazot PL; Tiligada E
Br J Pharmacol; 2020 Feb; 177(3):467-468. PubMed ID: 31994717
[TBL] [Abstract][Full Text] [Related]
33. Preclinical models of myocardial infarction: from mechanism to translation.
Martin TP; MacDonald EA; Elbassioni AAM; O'Toole D; Zaeri AAI; Nicklin SA; Gray GA; Loughrey CM
Br J Pharmacol; 2022 Mar; 179(5):770-791. PubMed ID: 34131903
[TBL] [Abstract][Full Text] [Related]
34. Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra.
Rajagopal K; Bryant AJ; Sahay S; Wareing N; Zhou Y; Pandit LM; Karmouty-Quintana H
Br J Pharmacol; 2021 Jan; 178(1):172-186. PubMed ID: 32128790
[TBL] [Abstract][Full Text] [Related]
35. Pulmonary hypertension in chronic obstructive pulmonary disease.
Gredic M; Blanco I; Kovacs G; Helyes Z; Ferdinandy P; Olschewski H; Barberà JA; Weissmann N
Br J Pharmacol; 2021 Jan; 178(1):132-151. PubMed ID: 31976545
[TBL] [Abstract][Full Text] [Related]
36. Serelaxin in clinical development: past, present and future.
Unemori E
Br J Pharmacol; 2017 May; 174(10):921-932. PubMed ID: 28009437
[TBL] [Abstract][Full Text] [Related]
37. Nicotinic ACh receptor α7 inhibits PDGF-induced migration of vascular smooth muscle cells by activating mitochondrial deacetylase sirtuin 3.
Li DJ; Tong J; Zeng FY; Guo M; Li YH; Wang H; Wang P
Br J Pharmacol; 2019 Nov; 176(22):4388-4401. PubMed ID: 30270436
[TBL] [Abstract][Full Text] [Related]
38. Mitochondrial function in the heart: the insight into mechanisms and therapeutic potentials.
Nguyen BY; Ruiz-Velasco A; Bui T; Collins L; Wang X; Liu W
Br J Pharmacol; 2019 Nov; 176(22):4302-4318. PubMed ID: 29968316
[TBL] [Abstract][Full Text] [Related]
39. The application of 'omics' to pulmonary arterial hypertension.
Harbaum L; Rhodes CJ; Otero-Núñez P; Wharton J; Wilkins MR
Br J Pharmacol; 2021 Jan; 178(1):108-120. PubMed ID: 32201940
[TBL] [Abstract][Full Text] [Related]
40. 'Conditioning the heart' - lessons we have learned from the past and future perspectives for new and old conditioning 'drugs'.
Weber NC
Br J Pharmacol; 2015 Apr; 172(8):1909-12. PubMed ID: 25824658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
